CLINICAL TRIALS PROFILE FOR VALSARTAN
✉ Email this page to a colleague
505(b)(2) Clinical Trials for valsartan
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Formulation | NCT04047940 ↗ | A Study of LY900020 in Healthy Chinese Participants | Completed | Eli Lilly and Company | Phase 1 | 2019-11-29 | This study will evaluate three new formulations of LY900020; a fixed dose, combination drug developed for people with type 2 diabetes mellitus. The study will be conducted in healthy participants to investigate the effect of different tablet formulations on the amount of LY900020 in the bloodstream. Side effects and tolerability will be documented. The study will last about 10 weeks for each participant, including screening and follow up. Screening is required within 28 days prior to entering the study. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for valsartan
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00034840 ↗ | Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose | Completed | Bayer | Phase 4 | 2001-10-01 | The primary objectives are to demonstrate that MICARDIS® (telmisartan) is statistically superior to Diovan® (valsartan) in reducing diastolic blood pressure (DBP) following a missed dose at the end of a 6 to 8-week treatment period as measured by the 24-hour ABPM mean and to demonstrate that MICARDIS® is statistically superior to Diovan® in reducing DBP during the last 6-hours of the 24-hour dosing interval as measured by ABPM following a dose of active study medication at the end of a 6 to 8-week treatment period. |
| NCT00034840 ↗ | Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose | Completed | GlaxoSmithKline | Phase 4 | 2001-10-01 | The primary objectives are to demonstrate that MICARDIS® (telmisartan) is statistically superior to Diovan® (valsartan) in reducing diastolic blood pressure (DBP) following a missed dose at the end of a 6 to 8-week treatment period as measured by the 24-hour ABPM mean and to demonstrate that MICARDIS® is statistically superior to Diovan® in reducing DBP during the last 6-hours of the 24-hour dosing interval as measured by ABPM following a dose of active study medication at the end of a 6 to 8-week treatment period. |
| NCT00034840 ↗ | Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose | Completed | Boehringer Ingelheim | Phase 4 | 2001-10-01 | The primary objectives are to demonstrate that MICARDIS® (telmisartan) is statistically superior to Diovan® (valsartan) in reducing diastolic blood pressure (DBP) following a missed dose at the end of a 6 to 8-week treatment period as measured by the 24-hour ABPM mean and to demonstrate that MICARDIS® is statistically superior to Diovan® in reducing DBP during the last 6-hours of the 24-hour dosing interval as measured by ABPM following a dose of active study medication at the end of a 6 to 8-week treatment period. |
| NCT00089518 ↗ | Optimal Treatment for Kidney Disease in HIV Infected Adults | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 | 1969-12-31 | The angiotensin receptor blocker (ARB) valsartan is a drug commonly used to treat high blood pressure. Valsartan may also help slow down the progression of kidney disease in HIV infected people. The purpose of this study is to compare valsartan and antiretroviral therapy (ART) to ART alone in slowing kidney disease progression in people with HIV. |
| NCT00097786 ↗ | Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications | Completed | Novartis Pharmaceuticals | Phase 3 | 2002-01-01 | This study is a test of the safety and effectiveness of two drugs, one for diabetes and one for hypertension, in keeping patients with high lab values of glucose from progressing to frank diabetes and developing cardiovascular complications. People in this study cannot have frank diabetes but are considered "borderline" based on blood tests. People in the study take none, one or both of the drugs and do not know which one(s) they are taking. |
| NCT00129233 ↗ | Comparison of Valsartan With Amlodipine in Hypertensive Patients With Glucose Intolerance | Completed | Nagoya University | Phase 4 | 2004-10-01 | Various guidelines recommended angiotensin converting enzyme (ACE) inhibitors or angiotensin Ⅱ receptor-1 blockers (ARBs) for hypertensive patients with diabetes on the basis of the cardiac- and reno-protective effects of these drugs. However, these recommendations could not be extrapolated to Japanese patients, because Japan has been known as a country with a low incidence of coronary artery disease and a high incidence of cerebrovascular disease. Furthermore, calcium channel blockers (CCBs) also were protective against renal function as well as ACE inhibitors in Japanese diabetic hypertensive patients. This study will test whether ARBs or CCBs are superior in treating Japanese diabetic hypertensive patients. |
| NCT00130156 ↗ | Effects of Combination Therapy With Alpha-1 Blocker (Bunazosin or Doxazosin) in the Treatment of Patients With Mild to Moderate Essential Hypertension | Completed | Eisai Co., Ltd. | Phase 4 | 2005-10-01 | The purpose of this study is to investigate the efficacy and safety of Bunazosin with Valsartin compared to Doxazosin with Valsartin for patients with mild to moderate essential hypertension accompanied by metabolic syndrome. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for valsartan
Condition Name
Clinical Trial Locations for valsartan
Trials by Country
Clinical Trial Progress for valsartan
Clinical Trial Phase
Clinical Trial Sponsors for valsartan
Sponsor Name
